Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

68 69 Next >

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist ↗

December 01, 2023

These stocks offer enormous long-term growth potential.

Via The Motley Fool

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

Biotech And Healthcare Portfolio Playbook For December 2023/24 ↗

November 27, 2023

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.

Via Talk Markets

5 Stocks You Can Confidently Invest $500 In Right Now ↗

November 27, 2023

These companies could significantly grow your investment over the long haul.

Via The Motley Fool

Is Vertex Pharmaceuticals Stock a Buy Now? ↗

November 16, 2023

The company is close to another breakthrough.

Via The Motley Fool

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

November 14, 2023

Via Benzinga

2 Healthcare Stocks That Could Help Set You Up for Life ↗

November 25, 2023

Both companies are leaders in their fields.

Via The Motley Fool

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree ↗

November 25, 2023

These innovators should have tremendous long-term growth prospects.

Via The Motley Fool

4 First-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

November 25, 2023

The innovation-fueled Nasdaq Composite is still 11% below its all-time high, which means bargains abound for opportunistic investors.

Via The Motley Fool

Topics Stocks

European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

November 23, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Prediction: 3 Stocks That Could Trounce the Market ↗

November 23, 2023

These stocks have what it takes to be huge winners over the next several years.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

November 21, 2023

Via Benzinga

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Via The Motley Fool

Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? ↗

November 19, 2023

The stock is trading below its peak, reached a couple of years ago.

Via The Motley Fool

Barron's Weekend Stock Picks: Disney, Palantir And Cisco's Calamitous Outlook ↗

November 18, 2023

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.

Via Benzinga

Why CRISPR Therapeutics Stock Is Jumping Again Today ↗

November 17, 2023

The stock continues to enjoy momentum from a key regulatory approval.

Via The Motley Fool

Williams-Sonoma, Uber And 2 Other Stocks Insiders Are Selling ↗

November 17, 2023

The Nasdaq 100 closed higher by 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’

November 16, 2023

Via Investor Brand Network

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug ↗

November 16, 2023

The drug will sell under the brand name Casgevy in the UK for two blood diseases.

Via Investor's Business Daily

What's Going On With Crispr Therapeutics Stock Thursday? ↗

November 16, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene-

Via Benzinga

CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy ↗

November 16, 2023

CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring.

Via InvestorPlace

UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia ↗

November 16, 2023

The U.K.

Via Benzinga

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

November 16, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 15, 2023

Via Benzinga

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks ↗

November 14, 2023

You might not get a better chance to invest in these disruptive companies.

Via The Motley Fool

2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher ↗

November 14, 2023

These stocks look reasonably priced today considering their long-term prospects.

Via The Motley Fool

Topics Stocks

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

November 12, 2023

Most stocks aren't truly revolutionary. These really are.

Via The Motley Fool

1 No-Brainer Stock to Buy and Hold for 10 Years ↗

November 11, 2023

This company has been in the news for much of the year.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

All News about Vertex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today